Physician profile
John R Meadows
NPI 1659459816
$1,184.46
in general payments reported to CMS, 2019-2025
19 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.51 · 2020: $152 · 2021: $236 · 2022: $319 · 2023: $196 · 2024: $113 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $424.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $271.21 | 2020-2025 | Orbactiv, Kimyrsa, Vabomere |
| E.R. Squibb & Sons, L.L.C. | $117.72 | 2019-2023 | Camzyos |
| Aurinia Pharma U.S., INC. | $98.70 | 2022-2024 | Lupkynis |
| Janssen Pharmaceuticals, INC | $93.13 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $81.17 | 2019-2021 | |
| Pfizer INC. | $75.40 | 2020-2023 | |
| Boston Scientific Corporation | $72.12 | 2023-2025 | Lux-Dx Insertable Cardiac Monitor, General - Therapies |
| Alexion Pharmaceuticals, INC. | $71.68 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $65.22 | 2024 | Xerava, Giapreza |
| Tetraphase Pharmaceuticals, INC. | $38.07 | 2025 | |
| Gilead Sciences, INC. | $32.60 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.05 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $28.75 | 2022 | |
| Amgen INC. | $28.21 | 2023 | Tavneos |
| Viatris Specialty LLC | $19.90 | 2025 | Yupelri |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $18.94 | 2021 | |
| Dexcom, INC. | $15.98 | 2023 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $15.15 | 2020 | |
| Biogen, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.